We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tumor Markers Associated with H. Pylori Infection

By LabMedica International staff writers
Posted on 19 Sep 2018
Helicobacter pylori infection is a major cause of several cancers such as gastric, pancreatic and lung. The relationship between H. pylori and tumor markers continues to remain unclear. As one of the leading causes of morbidity and mortality globally, cancer represents a major detrimental public health problem worldwide.

There are various known important tumor biomarkers in cancer progression such as carcinoembryonic antigen (CEA), cancer antigens (CA) 153, CA199, CA724, CA125 and alpha-fetoprotein (AFP) which have been shown in the past to have various evidence in diagnostic modalities. These tumor markers were reported to have a close relationship with specific cancers.

A team of scientists led by those at Aerospace Center Hospital (Beijing, China) carried out a observational retrospective study and recruited a total of 14,689 subjects were included and 6,493 (44.2%) subjects were infected by H. pylori. The subjects had a mean age of 45 ±18 years. There were 4,530 (31.0%) female subjects. H. pylori infection status was assessed by ELISA specific for anti-H. pylori antibodies, particularly IgG and IgM. If both serological testing results were positive, the subject was diagnosed as H. pylori infection.

Cut-off values were administered to distinguish whether tumor marker levels were normal or abnormal. According to previous studies, the cut-off values of serum CEA, AFP, CA199, CA724, CA153 and CA125 were set to 5 ng/mL, 10 ng/mL, 37 U/mL, 10 U/mL, 25 U/mL and 35 U/mL, respectively. The ratios of individual biomarkers were measured between the two groups. The ratio is defined according to the cut-off value. Abnormal ratio means the percentage of individuals with abnormal CEA (i.e., CEA>5 ng/mL) in total H. pylori (+) subjects or individuals with abnormal CEA in total H. pylori (−) subjects.

The scientists reported that after adjusting for the confounding factors, infections with H. pylori were found to be significantly associated with abnormal ratios in CEA, AFP and CA724 of H. pylori (+) to H. pylori (–) groups. Significant positive correlation was found between H. pylori infection and CEA values. Significant differences were found in both low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels between H. pylori (+) and H. pylori (−) groups.

The authors concluded that in their observational retrospective study illustrated that higher abnormal ratios of CEA, AFP and CA724 were observed in infected to uninfected subjects. Higher level of CEA was also found to be related to H. pylori infection after controlling confounders. The serological testing for the presence of two antibodies against H. pylori, IgG and IgM, indicate a past exposure to this bacterium rather than a current exposure. These findings could aid in the earlier diagnosis and intervention provided to better patient’s quality of life. The study was published on August 23, 2018, in the journal BMJ Open.

Related Links:
Aerospace Center Hospital


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.